*July 2022*
Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression. Benjamin P. Levy, MD, Chaitali Nangia, MD, Patty and George Hoag Cancer Center, Jessica Donington, MD, MSCR, Jonathan Riess, MD, Alexander Spira, MD, PhD, FACP, Heather Wakelee, MD. Watch the video here.
